Patents by Inventor Hyeon Jun SHIN

Hyeon Jun SHIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polycyclic aromatic compounds and organic electroluminescent devices using the same
    Patent number: 11985891
    Abstract: Disclosed are polycyclic aromatic compounds that can be employed in various organic layers of organic electroluminescent devices. Also disclosed are organic electroluminescent devices including the polycyclic aromatic compounds. The organic electroluminescent devices are highly efficient and long lasting and have greatly improved luminous efficiency.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: May 14, 2024
    Assignee: SFC Co., Ltd.
    Inventors: SungHoon Joo, Ji-Hwan Kim, Byung-sun Yang, Hyeon Jun Jo, Sungeun Choi, Su-jin Kim, Bong-Ki Shin
  • POLYCYCLIC COMPOUND AND ORGANOELECTRO LUMINESCENT DEVICE USING SAME
    Publication number: 20240122070
    Abstract: The present invention relates to a novel polycyclic compound employed in an organic layer of an organoelectro luminescent device, wherein the organoelectro luminescent device employing the compound according to the present invention has remarkably improved luminous efficiency and a long lifespan. According to the present invention, it is possible to implement a highly efficient and long-life organoelectro luminescent device that can be effectively applied to various display devices.
    Type: Application
    Filed: October 12, 2020
    Publication date: April 11, 2024
    Applicant: SFC CO., LTD
    Inventors: Bong-ki SHIN, Sung-hoon JOO, Byung-sun YANG, Ji-hwan KIM, Hyeon-jun JO, Sung-eun CHOI
  • Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same
    Patent number: 11352399
    Abstract: The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 7, 2022
    Assignee: GENESEN CO., LTD.
    Inventors: Sang Dun Choi, Hyuk Kwon Kwon, Hyeon Jun Shin, Xiang Ai Gui
  • PEPTIDE FOR TOLL-LIKE RECEPTOR (TLR) INHIBITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20200140504
    Abstract: The present invention relates to a fusion polypeptide that inhibits TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways as well as Toll-like receptor 4 (TLR4) and TLR3, and a pharmaceutical composition for preventing or treating TLR pathway mediated diseases. The fusion peptide of the present invention has an excellent effect of inhibiting TLR4 and various TLR pathways and can be effectively used in preventing and treating various TLR pathway mediated diseases caused by the signaling pathways, such as autoimmune diseases, inflammatory diseases and degenerative neurological diseases, by inhibiting the TLR mediated immune responses.
    Type: Application
    Filed: April 25, 2018
    Publication date: May 7, 2020
    Applicant: GENESEN CO., LTD.
    Inventors: Sang Dun CHOI, Hyuk Kwon KWON, Hyeon Jun SHIN, Xiang Ai GUI